Latest news and research on all cancers and treatments, updated several times a week
I am doing three cancer biomarkers tomorrow: CA19-9 and CEA to see what changes have taken place, even though it is only 2 weeks since my last test for these, and CA125. The latter compliments CA19-9 and helps distinguish between pancreatic cancer types and maybe prostatitis.
My reading of a few more research papers on CA19-9 shows it is generally thought as a good biomarker for pancreatic cancer, albeit mainly for monitoring its development rather than for screening.
I do a CT scan on Wednesday 17th Dec.
Clinical Focus: Renal Cell Carcinoma
Beginning with the introduction of targeted therapies, research and clinical activity in renal cell carcinoma have gained unprecedented momentum that has more than doubled median survival. The future continues to look bright, although substantial challenges still must be overcome. In this exclusive video report, ongoing activities and future goals in therapeutic development for RCC are discussed FULL STORY»
Beginning with the introduction of targeted therapies, research and clinical activity in renal cell carcinoma have gained unprecedented momentum that has more than doubled median survival. The future continues to look bright, although substantial challenges still must be overcome. In this exclusive video report, ongoing activities and future goals in therapeutic development for RCC are discussed FULL STORY»
Tambahkan Komentar